Evaluation of SAP (Seaprose S) in the Treatment of Sinusitis (2nd. Report)

A Double Blind Trial Comparing with Serratiopeptidase

Abstract

In a double blind trial Seaprose S, a proteinase, was compared with Serratiopeptidase in the treatment of chronic sinusitis.
1. In physicians' assessments of usefulness by the seven-point-rating-scale, Seaprose S tended to be better than Serratiopeptidase, and in the rate of usefulness “two”, “slightly useful” or better, Seaprose S was significantly better.
2. In physicians' assessments of global improvement by the same scales, Seaprose S was also significantly better than Serratiopeptidase.
3. The Seaprose S group was significantly better in the secondary assessment of overall improvement of subjective symptoms.
4. In physicians' assessments of overall improvement of objective symptoms, Seaprose S was significantly better than Serratiopeptidase.
5. Physicians' assessments of overall improvement in X-ray findings showed Seaprose S to be significantly better in the seven-point-rating-scale, and in the rate of usefulness “one”, moderately improved" or better.
6. The Seaprose S group had fewer subjective symptoms, in particular postnasal drip and nasal obstruction.
7. Side effects were observed in 3.9% of the Seaprose S group and 4.3% of the Serratiopeptidase group, not a significant difference.
The above results indicate that Seaprose S is useful in the treatment of chronic sinusitis.